Clinical trials: Eating
Obesity; Overweight
Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects
The primary objective of this study is to assess the efficacy of ROSE-010 on food intake in female subjects with overweight and obesity.
- Trial name
- NCT06621017
- Testing
- ROSE-010 99 mcg, ROSE-010 150 mcg
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Rose Pharma Inc
Binge Eating Disorder
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The primary objective of the study is to demonstrate the efficacy of SPD489 compared with placebo in adults (18 55 years of age inclusive) with moderate to severe Binge Eating Disorder at Visit 8 (Weeks 11 and 12) as measured by…
- Trial name
- NCT01718509
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 48 sites in United States, Germany
- Volunteers
- 390 people
- Sponsor
- Shire
Binge Eating Disorder
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The primary objective of the study is to demonstrate the efficacy of SPD489 compared with placebo in adults (18 55 years of age inclusive) with moderate to severe Binge Eating Disorder at Visit 8 (Weeks 11 and 12) as measured by…
- Trial name
- NCT01718483
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 50 sites in United States, Germany and 2 more
- Volunteers
- 383 people
- Sponsor
- Shire
Binge Eating Disorder
Open Label Extension in Adults With Binge Eating Disorder (BED)
To evaluate the safety and tolerability of SPD489 administered as a daily morning dose (50 or 70mg) in the treatment of moderate to severe binge eating disorder (BED) in adults
- Trial name
- NCT01657019
- Testing
- Lisdexamfetamine dimesylate
- Where
- 89 sites in United States, Germany and 1 more
- Volunteers
- 604 people
- Sponsor
- Shire
Binge-Eating Disorder
A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder
The primary objective of this study is to assess the efficacy of 2 doses of centanafadine sustained-release (SR) (200 milligrams [mg] and 400 mg total daily dose [TDD]) compared with placebo in adults with moderate to severe…
- Trial name
- NCT05113953
- Testing
- Centanafadine
- Where
- 25 sites in United States
- Volunteers
- 147 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Mental Health
An Evaluation of Innerview™, a Web-based Tool to Support the Integration of Mental Health in the Primary Care Setting
Innerview can address some of the challenges of integrating mental health and primary care by accurately and reliably collecting mental health evidence and activities directly from patients, and then organizing and automating…
- Trial name
- NCT02025647
- Where
- 5 sites in United States
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Pearson/Clinical Assessment
Nutrition, Healthy, Behavior, Eating
Good Bowls: Eat Well At Work
The goal of this clinical trial is to improve the health of workers at their worksite by providing subsidized healthy meals supported by nutrition education and behavioral nudges using mobile health and Bluetooth technology.
- Trial name
- EWAW (NCT05776303)
- Testing
- Good Bowls, Good Bowls + App Nudges
- Where
- United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Equiti Food, LLC
Binge Eating Disorder
Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder
To evaluate the efficacy of SPD489 compared to placebo in the treatment of moderate to severe binge eating disorder as measured by the number of binge days per week
- Trial name
- BED (NCT01291173)
- Testing
- lisdexamfetamine dimesylate (SPD489)
- Where
- 31 sites in United States
- Volunteers
- 271 people
- Sponsor
- Shire
Obesity
Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects
This will be a randomized, double blind, placebo controlled, 2 arm, parallel group, methodology study to assess the effect of 6 weeks of liraglutide administration on food intake in obese subjects.
- Trial name
- NCT03041792
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Pfizer
Obesity
A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide
This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat.
- Trial name
- NCT04081337
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Eli Lilly and Company
Binge Eating Disorder
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A study to evaluate a drug (dasotraline) on the safety, effectiveness and how well the body tolerates it, in adults with moderate to severe binge eating disorder
- Trial name
- NCT03107026
- Testing
- dasotraline 4mg, dasotraline 6mg
- Where
- 50 sites in United States
- Volunteers
- 491 people
- Sponsor
- Sumitomo Pharma America, Inc.
Anorexia Nervosa, Constipation
The Role of Lactobacillus Reuteri in Children and Adolescents With Anorexia Nervosa
The aim of this study is to investigate whether Lactobacillus reuteri could have a beneficial role in treatment of children and adolescents with Anorexia nervosa who develop motility disorder due to the malnutrition regarding the…
- Trial name
- NCT02004288
- Testing
- Lactobacillus reuteri Protectis DSM17938
- Where
- Croatia
- Volunteers
- 31 people
- Sponsor
- BioGaia AB
Rumination, Stress, Psychological
Testing a Digital Intervention for Adolescents
Teen participants (ages 13-17) will be randomly assigned to either an experimental (the Happify Teens digital platform), or a waitlist control group. The study includes an 8-week intervention period and a 1-month follow up period.
- Trial name
- NCT04567888
- Testing
- Happify Teens
- Where
- United States
- Volunteers
- 353 people
- Sponsor
- Happify Inc.
Binge-Eating Disorder
Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder
Placebo-controlled study to evaluate the efficacy and safety of oral ACT-539313 in the treatment of adults with moderate to severe binge eating disorder
- Trial name
- NCT04753164
- Testing
- ACT-539313
- Where
- 30 sites in United States
- Volunteers
- 136 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Binge Eating Disorder
Dasotraline Binge Eating Disorder Extension Study
Binge Eating Disorder Extension Study.
- Trial name
- NCT02684279
- Testing
- Dasotraline
- Where
- 57 sites in United States
- Volunteers
- 533 people
- Sponsor
- Sumitomo Pharma America, Inc.
Binge Eating Disorder
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
To evaluate maintenance of efficacy based on time to relapse between SPD489 (50 or 70mg) and placebo, as measured by the number of binge days (defined as days during which at least 1 binge episode occurs) per week as assessed by…
- Trial name
- NCT02009163
- Testing
- Lisdexamfetamine dimesylate
- Where
- 53 sites in United States, Canada and 3 more
- Volunteers
- 418 people
- Sponsor
- Shire
Inflammatory Bowel Diseases, Depressive Episode
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the impacts on quality-of-life outcomes and use of healthcare services in people aged 5 - 25 years…
- Conditions
- Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder
- Trial name
- NCT05206734
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 19,469 people, healthy volunteers welcome
- Sponsor
- Momentum Data